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preclinical data on RANK/RANKL inhibition in osteosarcoma 
and could serve as a hypothesis-generating approach for 
clinical trials in this patient population. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Osteosarcoma is a rare primary malignant tumour of 
bone that can often be cured with multimodal approach-
es including combination chemotherapy and surgery  [1] . 
Patients with primary osteosarcoma in the spine as well 
as male and older patients (aged >12 years) have an infe-
rior prognosis  [2, 3] . Treatment options are very limited 
in patients with inoperable locally advanced or metastat-
ic disease that has progressed after chemotherapy or ra-
diotherapy, and the outcome is poor  [4] . A recently pub-
lished phase II trial has suggested some benefit from 
treatment with the multi-target tyrosine kinase inhibitor 
sorafenib resulting in a clinical benefit rate of 29% (de-
fined as improvement in the Pain Analgesic Score via the 
Brief Pain Inventory score)  [5] . However, the benefit was 
short-lived, with a median progression-free survival of 4 
months and a median overall survival of 7 months. The 
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 Abstract 
 Background: There is no established systemic treatment op-
tion for unresectable osteosarcoma progressing after stan-
dard chemotherapy. A recently published clinical trial has 
demonstrated some activity of sorafenib in this situation. 
Preclinical research suggests a role for the inhibition of the 
receptor activator of nuclear factor-ĸB ligand (RANKL), but 
no clinical data have been reported so far.  Case Report: A 
37-year-old man was diagnosed with unresectable osteo-
blastic, osteoblastoma-like osteosarcoma in the C7/Th1 ver-
tebra. The tumour progressed locally despite two lines of 
chemotherapy and stereotactic radiotherapy. On treatment 
with sorafenib and denosumab, a complete metabolic re-
mission was achieved and is ongoing for over 18 months. 
Immunohistochemistry revealed an overexpression of RANK 
and RANKL in the patient’s primary tumour.  Discussion: This 
is the first report of activity achieved by the combination of 
the tyrosine kinase inhibitor sorafenib and the RANKL inhib-
itor denosumab in a patient with osteosarcoma. It confirms 
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receptor activator of nuclear factor-ĸB (RANK) signal-
ling pathway is activated by RANK ligand (RANKL) and 
is essential for bone homeostasis  [6] . Osteoblasts secrete 
RANKL, which leads to the differentiation and activation 
of osteoclasts promoting the release of bone-derived 
growth factors and osteolysis  [6] . RANK signalling has 
been associated in preclinical osteosarcoma models with 
increased cell mobility and anchorage-independent 
growth  [7] . In vitro studies in osteosarcoma cell lines us-
ing either osteoprotegrin (a physiological antagonist of 
RANK) or RANK-Fc protein to inhibit RANK signalling 
resulted in a reduction in osteosarcoma cell migration, 
invasion ability and anchorage-independent viability  [8, 
9] . In mice models, a reduction in tumour incidence, local 
tumour growth and dissemination of lung metasta-
ses translating into prolonged survival of mice could be 
demonstrated by the same methods  [10, 11] . Therefore, 
RANKL may represent a potential therapeutic target in 
osteosarcoma; however, so far, no clinical data using 
RANKL inhibition have been reported.
 Case Presentation 
 A 37-year-old otherwise healthy man was initially diagnosed 
histologically with an osteoblastoma in the Th1 vertebra. Curet-
tage was performed, but the lesion recurred within 6 months in 
Th1 and C7. A pathology review revealed the diagnosis of an os-
teoblastic, osteoblastoma-like osteosarcoma. The tumour was not 
a b
a b
 Fig. 1.  18 F-fluorodeoxyglucose positron emission tomography CT before ( a ) and 8 months after ( b ) the initiation 
of sorafenib/denosumab. 
 Fig. 2.  a Immunhistochemistry of RANK (clone 80707, dilution 1: 400; R&D Systems) demonstrating cytoplas-
matic positivity in the multinucleated giant cells. ×200.  b Immunohistochemistry of RANKL (clone 12A668, di-
lution 1: 400; Abcam) showing cytoplasmatic expression in the mononuclear, osteoid-producing tumour cells. 
×200. 
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primarily resectable in toto, and, after interdisciplinary discussion, 
the patient was treated with induction chemotherapy (cisplatin, 
doxorubicin, high-dose methotrexate) in analogy to the EURA-
MOS protocol  [12] . After 3 cycles, local progression was noted, 
and the tumour remained unresectable, mainly because the patient 
was afraid of the potential surgical consequences. Instead, stereo-
tactic radiotherapy (total dose: 80 Gy) was administered with little 
effect, and, after 2 months, further local progression was observed, 
and a new lesion at the resection margin of rib 1 was found. The 
patient received 3 cycles of second-line chemotherapy with ifos-
famide, carboplatin and etoposide without any effect. At this point 
in time, treatment with sorafenib (400 mg twice daily) and deno-
sumab (120 mg every 4 weeks) was initiated. The treatment has 
been well tolerated, with grade 2 hand-foot syndrome as the main 
side effect. A metabolic complete remission with intense calcifica-
tions at the areas of former  18 F-fluorodeoxyglucose uptake (C7, 
Th1, rib 1) was noted in a positron emission tomography CT 8 
months after initiation of treatment, with ongoing response and 
lack of further metastases after currently 18 months of treatment 
( fig. 1 ). Immunohistochemistry has been performed on formalin-
fixed tissue of the patient’s primary tumour, demonstrating posi-
tivity for RANK in multinucleated giant cells and cytoplasmatic 
expression of RANKL in the mononuclear, osteoid-producing tu-
mour cells ( fig. 2 ).
 Discussion 
 RANK and RANKL have been shown to be overex-
pressed in osteosarcoma patients and appear to be related 
to inferior outcome  [13, 14] . In a retrospective study on 
91 patients, overexpression of RANK and RANKL by im-
munohistochemistry was found in 69 and 9%, respective-
ly, and RANK was associated with inferior disease-free 
survival  [13] . Another retrospective study included 40 
patients, and positivity for RANK and RANKL was found 
in 50 and 75%, respectively, and RANKL was related to a 
poor response to chemotherapy and inferior overall sur-
vival  [14] . Denosumab is a fully human monoclonal an-
tibody against RANKL and effectively blocks the interac-
tion between RANKL and RANK, leading to decreased 
bone resorption  [15] . Denosumab is well tolerated and 
used in the treatment of osteoporosis as well as in patients 
with bone metastases from solid tumour, reducing the 
number of skeletal-related events  [16] . It has also shown 
very encouraging activity in giant cell tumour of bone, a 
locally aggressive primary bone tumour in which RANKL 
plays a critical role in pathogenesis  [17] , and this led to 
the approval of denosumab for the treatment of giant cell 
tumour by the European Medicines Agency. In vitro 
studies show that RANK activation initiates multiple sig-
nalling pathways beyond the usual target of nuclear 
factor-ĸB. Especially the ERK1/2 pathway has been found 
to be crucial for the promotion of anchorage-indepen-
dent survival and invasion of osteoblastic cells  [7] . This is 
even more interesting since it appears that a blockade of 
the ERK1/2 pathway might be one of the mechanisms of 
action of sorafenib in osteosarcoma  [18, 19] . A synergistic 
effect of the combination of denosumab and sorafenib 
can therefore be proposed. No preclinical data have been 
published investigating this hypothesis.
 To our knowledge, no reports on the treatment with 
denosumab or the combination of sorafenib and deno-
sumab in the setting of osteosarcoma have been pub-
lished so far. The exceptional response in our patient and 
the outlined preclinical evidence might serve as hypoth-
esis generating and trigger an interest in prospective tri-
als.
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